<DOC>
	<DOCNO>NCT02767193</DOCNO>
	<brief_summary>single-center , national clinical trial , phase I , randomize ( 1 : 1 : 1 : 1 ) , prospective , placebo-controlled , partially mask , parallel group . Patients assign one follow four arm : 3 immunization dendritic cell / 3 immunization dendritic cell pegylated interferon + / 3 immunization placebo / 3 immunization placebo pegylated interferon .</brief_summary>
	<brief_title>Safety Immunogenicity Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Patient &gt; 18 year age ; 2 . Voluntarily sign informed consent ; 3 . Men woman negative pregnancy test inclusion study ; 4 . HIV infection test ( positive antibody HIV1 detectable viral load ) ; 5 . Patient must stable treatment cART least 1 year 6 . The average measurement CD4 year start cART equal great 350 cell / mm3 7 . The number CD4 + enrollment must equal great 450 cell / mm3 ; 8 . Plasma HIV viral load undetectable least 6 month inclusion study , least two determination ( occasional blip undetectable level allow ) . 1 . Treatment suboptimal regimen ( less 3 antiretroviral drug ) start cART ; 2 . History C CDC event ; 3 . Interruption cART inclusion study ; 4 . Pregnancy woman become pregnant next month ; 5 . Active opportunistic infection , active infection cancer within 30 day prior screen visit ; 6 . Therapy immunomodulatory agent , include cytokine ( eg IL2 ) gamma globulin chemotherapy within 90 day prior screen visit ; 7 . Use anticoagulant medication ; 8 . Use investigational drug within 90 day prior study entry ; 9 . Virological failure prior antiretroviral treatment / mutation confer resistance antiretroviral drug ; 10 . Uncontrolled psychiatric disorder ; 11 . Platelet count &lt; 80,000 / mm3 ; 12 . Values ? ? hemoglobin &lt; 12g / dL ; 13 . Patients active uncontrolled autoimmune disease ; 14 . Using contraindicated drug accordance Summary Product Specifications pegylated interferon ; 15 . Childbearing , potential childbearing use highly effective contraception ; 16 . Any problem accord investigator could interfere evaluation objective . 17 . Any contraindication use interferon peg accordance Summary Product Characteristics .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>